Background. The development of direct-acting antivirals in recent years has dramatically enhanced rates of viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection. To determine true treatment efficacy and define the most appropriate retreatment, it is important to distinguish virologic relapse from reinfection when patients in whom HCV is eradicated during treatment become infected with a new HCV strain after treatment.
Hepatitis C virus (HCV), as a plus-strand RNA virus without a DNA intermediate, has no latent forms or possibility of integration into the host genome. Thus, survival of the virus relies on ongoing replication. This explains the high efficacy of combination regimens of direct antiviral agents (DAAs) with complete suppression of HCV replication for viral eradication. In recent years, DAA-based therapy has dramatically enhanced rates of sustained virologic response (SVR) to >90% in patients with chronic HCV infection. The pangenotypic NS5B HCV inhibitor sofosbuvir (SOF) has demonstrated high efficacy in patients infected with HCV in combination with ledipasvir (LDV) for genotype (GT) 1, 4, 5, and 6 [1] [2] [3] [4] [5] and in combination with ribavirin (RBV), with or without pegylated interferon for GT2-3 HCV [6] [7] [8] [9] [10] [11] . Moreover, patients with prior SOF-based treatment failure have been successfully retreated with the fixed-dose combination of LDV/SOF plus RBV [12, 13] .
Undetectable HCV RNA (<25 IU/mL) 12 weeks after the end of treatment (SVR12) is used to define the rate of viral eradication as a primary end point in all interferon-free DAA combination trials, given the demonstrated high concordance of SVR12 and SVR24 with historic, interferon-based regimens and supportive phase 2 data with SOF-based regimens [14] [15] [16] . Moreover, in phase 3 studies of SOF, 99.7% concordance was observed between SVR12 and SVR24 [17, 18] .
To determine true treatment efficacy and define the most appropriate retreatment for patients with recurrent viremia, it is important to distinguish virologic relapse from reinfection when in patients whom HCV is eradicated during treatment later become infected with a new HCV strain. Because patients do not have protective immunity, reinfection after subsequent exposure has been clearly documented. In the current study, we investigated the prevalence of late recurrent viremia ( patients who had SVR12 but had detectable HCV RNA at follow-up week 24) in phase 3 clinical trials LDV/SOF and SOF, and we used refined phylogenetic analysis to distinguish virologic relapse from reinfection.
METHODS

Clinical Trials
We performed sequencing analysis of NS5B on specimens from patients enrolled in 11 SOF phase 3 clinical trials: POSITRON [19] , FUSION [19] , FISSION [20] , VALENCE [11] , GS-US-334-0119 [21] , PHOTON-1 [22] , PHOTON-2 [23] , NEUTRINO [20] , ION1 [1] , ION2 [2] , and ION3 [24] (Table 1) . Information regarding each clinical trial can be found at www.clinicaltrials. gov. All patients included in clinical trials described in this study have provided informed consent in writing, and the study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by the appropriate institutional review committee. Treatment adherence was measured by pill count.
Deep Sequencing Analyses
NS5B deep sequencing analysis was performed at baseline and virologic failure time point for patients who received ≥1 dose of an SOF-containing regimen, did not achieve SVR owing to virologic failure or early discontinuation, and had an HCV RNA level ≥1000 IU/mL. NS5B PCR amplicons at baseline and after baseline time points, generated by DDL Diagnostic Laboratory, were subjected to deep sequencing using the Illumina MiSeq deep sequencing platform (Illumina) at DDL Diagnostic Laboratory or WuXi (AppTec). Internally developed software was used to process and align sequencing data in order to identify the substitutions present at levels >1% [25, 26] . In addition, "consensus" sequences were generated for each sample with inclusion of mixtures of amino acids when present at between 15% and 85%. For patients with late viral relapse after SVR12, deep sequencing of NS3 and NS5A was also performed. Moreover, when available, multiple samples at baseline and after treatment were analyzed for each patient (Supplementary Table 1 ).
Short Fragment NS5B Population Sequencing
For patient samples in which NS5B deep sequencing was not successful owing to full-length NS5B amplification failure, population sequencing of a short-fragment (amino acids 230-340) HCV NS5B was performed by DDL Diagnostic Laboratory using reverse transcription polymerase chain reaction (PCR) and standard Sanger sequencing of the bulk PCR product.
Phylogenetic Analyses of Consensus Sequences
Baseline and posttreatment consensus sequences were aligned for each patient using ClustalW software (version 2.1) [27] . Combined and individual alignments and phylogenetic trees were performed for each HCV subtype, including longitudinal samples from patients with relapse before posttreatment week 12 as control for viral genetic drift. Maximum likelihood phylogenetic trees were inferred using GARLi software (version 2.0), which optimizes the substitution model iteratively [28] . Default parameters were used. The confidence of the braches was assessed by approximate likelihood-ratio test [29] using PhyML 3.0 software [30] and bootstrap of 1000 replicates, and a consensus tree was generated using PAUP software (version 4.0b10). Branches with P values <.001 or a bootstrap value >70 were considered supported. The phylogenetic trees were visualized using FigTree software (version 1.3.1).
Phylogenetic Analyses of HCV Quasispecies
The deep sequencing reads for each time point, 150 base pairs long, were aligned to NS5B consensus sequence from the baseline patient sample. Regions of 150 nucleotides with genetic changes between baseline and posttreatment sequences for each patient were identified and extracted for phylogenetic analysis. Data were compressed to unique reads. Maximum likelihood phylogenetic tree was constructed as described above.
Genetic Distance Between Baseline and Posttreatment HCV Sequences
The number of nucleotide substitutions per site between baseline and posttreatment sequences were conducted using the Tamura-Nei model [31] in MEGA6 software [32] . The rate variation among sites was modeled with a gamma distribution (shape parameter, 0.5). First, second, third, and noncoding codon positions were included. All positions containing gaps and missing data were eliminated. Ambiguous codes containing a mix of nucleotide present at baseline were not counted as changes.
RESULTS
In the LDV/SOF and SOF phase 3 studies, recurrent viremia after the discontinuation of HCV treatment accounted for all virologic failures among treatment-adherent patients and the vast majority of the cases of recurrent viremia occurred early after stopping treatment (at posttreatment week 4 or 12). Across 11 phase 3 SOF and LDV/SOF clinical trials, only 12 of 3004 patients had detectable HCV RNA after SVR12 (Table 2) . Of these 12 patients with late recurrent viremia, 11 had the same HCV genotype/subtype at baseline and at the time of recurrence.
To distinguish reemergence of initial virus from HCV reinfection, phylogenetic analyses of multiple genes (NS3/4A, NS5A, and NS5B) from baseline and posttreatment samples were generated for each patient. Maximum likelihood phylogenetic trees were inferred for GT1a, GT1b, and GT3a consensus sequences generated from deep sequencing data, including sequences from patients with early relapse as a control for genetic drift over the same time period.
Of the 12 patients with late recurrent viremia (between SVR12 and SVR24 time points), 5 had minimal genetic changes between baseline and posttreatment NS5B consensus sequences, indicated by clustering and separation from all other sequences by a supported branch in the phylogenetic tree (Figure 1A and 1B; Table 2 ). These 5 patients all had GT3a infection before treatment and at the time of late relapse, consistent with higher overall relapse rate in GT3. Of note, HCV RNA declined to undetectable levels during 12 or 24 weeks of treatment with SOF plus RBV for each patient, remained undetectable in all posttreatment samples through week 12 after treatment, but was detectable at week 24.
No known drug resistance-associated variants were detected with deep sequencing analysis in these patients. Moreover, investigation of the viral quasispecies population at baseline and after treatment, by performing phylogenetic analysis of individual reads covering a partial region within NS5B, showed intermingling of sequences and minimal genetic changes (Figure 2A,  Supplementary Figure 1) . A similar pattern was observed in the quasispecies phylogenetic analyses for the control patients with relapse at earlier time points (week 4 or 12 after treatment) (Supplementary Figure 3) . This suggests that, despite viral suppression to undetectable levels in the blood during 12-or 24-week treatment and after cessation of treatment for up to 24 weeks, the HCV present at baseline persisted in the liver or in another compartment and reemerged in the blood 24 weeks after treatment.
In another 5 of the 12 patients with late recurrent viremia, phylogenetic analyses of NS5B sequences showed that the virus present at baseline was significantly unrelated to that present after treatment ( Figure 1 ; Table 2 ). The baseline sequence did not cluster with posttreatment sequence, which were more closely related to other patient sequences than to the baseline sequence. Concordant results were obtained for phylogenetic analyses of NS3 and NS5A sequences from these patients, as well as inclusion of sequences of multiple time points at baseline and after treatment when sequences were available.
The results strongly suggest that these patients were reinfected with a new HCV strain after eradication of their initial infection. In 4 of the 5 patient, the new infection was sustained by the same subtype as present at baseline (GT1a, n = 2; GT1b, n = 1; GT3a, n = 1) and in 1 patient the new infection was a different genotype (GT4d at baseline and GT1a after treatment). The GT1a sequences from patients with early relapse up to 12 weeks after treatment (n = 19), which were included as a control for genetic drift during the same time period, showed minimal genetic changes between baseline and after treatment, with an average genetic diversity of baseline and posttreatment sequences of 0.002 nucleotide substitutions per site (range, 0.00-0.022). For the patients with reinfection of the same subtype present at baseline the average genetic distance between baseline and posttreatment sequences was significantly higher (P < .001), at 0.08 nucleotide substitutions per site (range, 0.061-0.104).
To control for a possible coinfection at baseline, which could provide a similar phylogenetic pattern, phylogenetic analyses of the viral quasispecies at baseline and after treatment were performed for each patient. A possible coinfection would show 2 subpopulations at baseline and intermingling of posttreatment sequences with 1 of these subpopulations. In none of these patients was this pattern observed ( Figure 2B ; Supplementary Figure 2) . Overall, these analyses provide evidence that these patients, who were successfully treated with the SOF-based regimen and achieved HCV eradication, became infected with a different HCV strain after treatment.
In 2 patients, the baseline and posttreatment sequences were distantly related ( Figure 1B and 1C) ; the sequences were grouped in the phylogenetic tree, but the branches separating them were long. To further investigate whether these patients experienced reinfections or virologic relapse, phylogenetic analyses of the viral quasispecies was inferred. The generated trees showed that the viral population present at baseline did not intermingle with that present after treatment, suggesting reinfection of a distantly related virus after treatment ( Figure 2C) . Moreover, the genetic distances between baseline and posttreatment NS5B sequence were 0.045 and 0.042 nucleotide substitutions per site, more similar to the average genetic distance of the unrelated reinfection cases than to the distances in the patients experiencing late relapse, 0.08 (range, 0.061-0.104) and 0.005 (0.003-0.009), respectively. Phylogenetic analyses of patients experiencing early recurrent viremia before posttreatment week 12 in these phase 3 trials did not reveal any instances of reinfection; thus all these cases represent true virologic relapse.
DISCUSSION
To determine true treatment efficacy and define the most appropriate retreatment strategy for patients with recurrent viremia after DAA-based therapy, it is important to distinguish virologic relapse of the initial HCV infection from reinfection wherein patients who achieve HCV eradication during treatment become infected with a new HCV strain after treatment. Because patients do not have protective immunity, reinfection after exposure has been clearly documented. In the current study, we analyzed patients with late recurrent viremia after SOF or LDV/SOF treatment to distinguish patients with virologic relapse from those with reinfection.
Among treatment-adherent patients in the LDV/SOF and SOF phase 3 studies (including >3000 patients), most patients with recurrent viremia after discontinuation of HCV treatment had recurrence early after stopping treatment ( posttreatment week 4 or 12). This is consistent with incomplete eradication of the original HCV from the liver, followed by robust viral replication and emergent viremia, known as relapse. The incidence of late recurrent viremia was exceedingly low; only 12 patients had detectable HCV RNA between SVR12 and SVR24. Of these 12 patients, 11 had the same HCV genotype/subtype at baseline and at recurrence. Interestingly, with phylogenetic analyses we determined that 7 of 12 patients (58%) with late recurrent viremia had been reinfected and did not represent the persistence and late emergence of the primary HCV infection (virologic relapse).
This finding may have implications for selection of optimal retreatment strategies because reinfection may be simpler to treat owing to the lack of exposure of the current viral quasispecies to therapy, whereas virologic relapse cases may have selected viral variants with reduced susceptibility. It also has implication for how long and what it takes to eliminate HCV and emphasizes the need to extend the continuum of HCV care beyond the SVR12 time point in persons at risk for reinfection. Further studies are needed to investigate risk factors in patients with reinfection and optimal harm reduction interventions to prevent reinfections. Furthermore, these data underscore the potential role of HCV vaccine strategies for preventing both primary infection and reinfection in those whose infections are cured with HCV DAA regimens. Based on recent data in which GT3 patients whose infection relapsed after SOF-based treatment received retreatment with SOF, RBV, and pegylated interferon for 12 weeks, the SVR12 rate was 91%-100% [33] , suggesting that a SOF-based retreatment strategy could be successful in patients with virologic relapse.
Distinguishing reinfection from late virologic relapse might be difficult to perform in routine clinical practice owing to several factors. First, when the same HCV subtype is identified at baseline and after treatment, phylogentic analyses of baseline and posttreatment sequences are needed to distinguish reinfection from virologic relapse, and these may not be readily available in routine clinical practice. In the setting of late recurrent viremia, clinicians must consider the possibility of reinfection and carefully evaluate the patient's recent potential exposure to HCV infection through high-risk behaviors, such as injection drug use or, in the case of men who have sex with men, traumatic sexual practices [34, 35] . In the absence of reported potential exposures, reinfection and late virologic relapse may be difficult to distinguish in clinical practice, and further studies are needed to establish optimal retreatment strategies in such patients. Figure 2 . Differentiating reinfection from late relapse by means of quasispecies diversity. Maximum likelihood phylogenetic tree of hepatitis C virus (HCV) quasispecies at baseline and after treatment. A, Quasispecies phylogenetic tree of patient 9, experiencing late virologic relapse. HCV quasispecies intermingle between baseline and follow-up at week 24 after end of treatment (FU-24), which suggests outgrowth of baseline virus at relapse. B, Quasispecies phylogentic tree of patient 3, experiencing reinfection. HCV variants at baseline and FU-24 are separated from each other with no intermixing, which suggests reinfection with no evidence of double infection at baseline. Clusters were separated by supported branch (bootstrap >70). C, Quasispecies phylogentic tree of patients 6 and 7, with distantly related HCV. No intermingling were observed between variants at baseline and the relapse time point in these 2 patients with late relapse, suggesting reinfection with a related HCV strain at the relapse time point. For both patients 6 and 7, clusters were separated by supported branch (bootstrap >70).
In summary, the prevalence of late recurrent viremia was low in patients achieving SVR after SOF-based therapies. Fifty-eight percent of patients (7 of 12) with late recurrent viremia had HCV reinfection. This finding has implications for determining true treatment efficacy and selecting optimal retreatment strategies.
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